Senseonics Holdings/$SENS
1D1W1MYTD1Y5YMAX
Capital at risk
About Senseonics Holdings
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
- Ticker
- $SENS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 130
- Headquarters
- Germantown, United States
- Website
- www.senseonics.com
SENS Metrics
BasicAdvanced
$517M
-
-$2.26
1.08
-
Price and volume
Market cap
$517M
Beta
1.08
52-week high
$10.15
52-week low
$4.79
Average daily volume
764K
Financial strength
Current ratio
6.745
Quick ratio
6.197
Long term debt to equity
0.685
Total debt to equity
0.696
Interest coverage (TTM)
-20.96%
Profitability
EBITDA (TTM)
-106.509
Gross margin (TTM)
54.87%
Net profit margin (TTM)
-225.34%
Operating margin (TTM)
-223.22%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-41.41%
Return on equity (TTM)
-118.24%
Valuation
Price to revenue (TTM)
9.776
Price to book
5.72
Price to tangible book (TTM)
5.72
Price to free cash flow (TTM)
-4.837
Free cash flow yield (TTM)
-20.68%
Free cash flow per share (TTM)
-2.022
Growth
Revenue change (TTM)
90.63%
Earnings per share change (TTM)
12.89%
3-year revenue growth (CAGR)
38.04%
10-year revenue growth (CAGR)
119.15%
3-year earnings per share growth (CAGR)
-5.72%
10-year earnings per share growth (CAGR)
-18.12%
Bulls say / Bears say
Senseonics completed the acquisition of U.S. Eversense distribution assets from Ascensia, bringing commercialization in-house and improving margin capture. (Reuters)
Amendment to expand the Hercules loan facility to $140 million provides non-dilutive funding to support commercial expansion and R&D. (Reuters)
Initial full-year 2026 global net revenue guidance of $58 million to $62 million represents anticipated 65–76% year-over-year growth, underpinning strong sales momentum. (Reuters)
Full-year 2026 gross margin guidance of approximately 50% trails CGM industry peers, limiting near-term profitability potential. (Reuters)
Analysts forecast a Q1 2026 net loss of $0.43 per share, reflecting persistent unprofitability despite revenue gains. (Reuters)
An $80 million public offering of common stock and pre-funded warrants in April 2026 increases share count and may exert downward pressure on the stock. (Reuters via TradingView)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
SENS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.